| Expression pattern: |
UP |
| Associated gene: |
AR, ADAR2, FNTA, KRAS, ERK1/2, MEK1/2 |
| Associated microRNA: |
miR-370-3p, miR-328-5p, miR-920 |
| Biological function: |
circFNTA promotes bladder cancer cell invasion, metastasis, and cisplatin chemo-resistance; depletion of circFNTA suppresses xenograft growth and lung metastasis and increases cisplatin chemo-sensitivity. |
| Molecular mechanism: |
AR represses ADAR2 to increase circFNTA; circFNTA sponges miR-370-3p to increase FNTA expression, thereby activating KRAS signaling and downstream ERK1/2 and MEK1/2 phosphorylation. |
| Biological pathway or process: |
ERK (promotes); invasion (promotes); metastasis (promotes); drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
RT-qPCR; RNase R Treatment; FISH / smFISH; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; ChIP / ChIP-seq; Transfection; MTT; Transwell Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circFNTA is elevated in bladder cancer tissues and may be a therapeutic target to suppress BCa metastasis and increase cisplatin chemo-sensitivity. |
| Description: |
circFNTA is up-regulated in bladder cancer tissues and cell lines. It promotes bladder cancer invasion, metastasis, and cisplatin chemo-resistance through an AR/ADAR2/circFNTA/miR-370-3p/FNTA/KRAS signaling axis, and circFNTA depletion suppresses tumor growth and lung metastasis in vivo. |
| Confidence score: |
0.8322 |